U.S. FDA Approves Novocure's Optune Pax(R) for the Treatment of Locally Advanced Pancreatic Cancer

Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) approved Optune Pax (R) for the treatment of adult patients with locally advanced pancreatic cancer concomitant ...
Le Lézard

U.S. FDA Approves Novocure's Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer

Novocure announced today that the U.S. Food and Drug Administration (FDA) approved Optune Pax® for the treatment of adult ...